These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 22831988

  • 1. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM, Lee WJ, Han SS, Park SJ, Kim TH, Koh YH, Kim HB, Hong EK, Park JW, Kim CM.
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [Abstract] [Full Text] [Related]

  • 4. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD.
    Cancer; 2004 Aug 01; 101(3):578-86. PubMed ID: 15274071
    [Abstract] [Full Text] [Related]

  • 5. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
    Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N.
    Jpn J Clin Oncol; 2006 Sep 01; 36(9):552-6. PubMed ID: 16887837
    [Abstract] [Full Text] [Related]

  • 6. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Woo SM, Lee WJ, Kim JH, Kim DH, Han SS, Park SJ, Kim TH, Lee JH, Koh YH, Hong EK.
    Chemotherapy; 2013 Sep 01; 59(3):232-8. PubMed ID: 24356333
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
    Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH.
    Cancer; 2006 Jan 15; 106(2):361-5. PubMed ID: 16342166
    [Abstract] [Full Text] [Related]

  • 8. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A, Gramaticu I, Dinu I, Gheorghe L, Alexandrescu S, Buica F, Luca I, Becheanu G, Herlea V, Simionov I, Hrehoret D, Lupescu I, Popescu I, Diculescu M.
    J Gastrointestin Liver Dis; 2012 Sep 15; 21(3):277-84. PubMed ID: 23012669
    [Abstract] [Full Text] [Related]

  • 9. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
    Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH.
    Jpn J Clin Oncol; 2007 Nov 15; 37(11):829-35. PubMed ID: 17951334
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK.
    Jpn J Clin Oncol; 2007 Jan 15; 37(1):30-7. PubMed ID: 17272321
    [Abstract] [Full Text] [Related]

  • 11. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM, Song MK, Choi YJ, Kim GH, Shin HJ, Song GA, Chung JS, Cho GJ.
    Jpn J Clin Oncol; 2009 Jan 15; 39(1):43-8. PubMed ID: 18997184
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH, Wang FH, Jiang WQ, Xiang XJ, Deng YM, Hu GQ, Xu DM, Chen Y, Lin Q, He YJ.
    Cancer Chemother Pharmacol; 2008 Aug 15; 62(3):539-44. PubMed ID: 18172651
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
    McPartlin AJ, Mais K, Barker C, Swindell R, Mitchell K, Sykes A, Lee L, Yap B, Slevin NJ.
    Chemotherapy; 2013 Aug 15; 59(1):1-7. PubMed ID: 23635527
    [Abstract] [Full Text] [Related]

  • 14. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ, Ou XQ, Chen ZB, Liao H, Peng YL, Wang SY, Zhang HY, Lin Z.
    Cancer Chemother Pharmacol; 2013 Aug 15; 72(2):323-8. PubMed ID: 23728706
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J, Merl M, Lee MX, Kaley K, Saif MW.
    Expert Opin Drug Saf; 2010 Mar 15; 9(2):207-13. PubMed ID: 20095915
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, Pennucci C, Sanguinetti F, Lombardi M, Nicoli N.
    Cancer; 2005 Apr 01; 103(7):1402-7. PubMed ID: 15726542
    [Abstract] [Full Text] [Related]

  • 17. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
    Jung JH, Lee HS, Jo JH, Cho IR, Chung MJ, Bang S, Park SW, Song SY, Park JY.
    Chemotherapy; 2017 Apr 01; 62(6):361-366. PubMed ID: 28848173
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M, Working Group of Internal Oncology.
    Eur J Cancer; 2014 Dec 01; 50(18):3125-35. PubMed ID: 25446376
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
    Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK.
    Ann Oncol; 2003 Jul 01; 14(7):1115-20. PubMed ID: 12853355
    [Abstract] [Full Text] [Related]

  • 20. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K.
    Cancer Chemother Pharmacol; 2005 Jul 01; 56(1):10-4. PubMed ID: 15782313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.